Roche Showcases Groundbreaking Cancer Research at ESMO 2025

Roche announced it will present over 30 abstracts on more than 10 different types of cancer at the European Society for Medical Oncology (ESMO) Congress 2025, highlighting its commitment to progressing cancer care. 

These presentation topics encompass breast, lung, gastrointestinal and genitourinary cancers and illustrate Roche’s commitment to innovation to develop new transformative medicines for some of the most difficult to treat cancers.

Among the significant data, giredestrant is showcased with its primary results from the phase III evERA Breast Cancer study, the first positive head-to-head trial of a selective oestrogen receptor degrader (SERD) as a regimen versus standard therapy, in the post CDK inhibitor treatment setting. The study met both co-primary endpoints demonstrating statistically significant improvement in progression-free survival in both the overall population and ESR1-mutated population.

Also Read: Lilly Highlights Verzenio and Pipeline Progress at ESMO 2025

Also to note, Tecentriq (atezolizumab) results were presented from the IMvigor011 phase III trial, the first of its kind to use a circulating tumour DNA (ctDNA)-guided approach to treatment in muscle-invasive bladder cancer (MIBC) post-surgery. In the study, patients with detectable ctDNA who received Tecentriq experienced meaningful improvement in disease-free and overall survival, in a presentation made during the Presidential Symposium.

Alecensa (alectinib) continues to establish its place as a leader for the treatment of ALK-positive non-small cell lung cancer (NSCLC) following final overall survival data from the pivotal ALEX study and updated adjuvant data from the ALINA trial, confirming its status as standard of care.

Roche has been revolutionizing cancer treatment through innovation in science and diagnostics for more than 60 years, staying committed to their vision of changing the future of care in cancer.